Advertisement
Canada markets open in 2 hours 16 minutes
  • S&P/TSX

    22,107.08
    +194.56 (+0.89%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CAD/USD

    0.7357
    -0.0016 (-0.21%)
     
  • CRUDE OIL

    82.30
    +0.95 (+1.17%)
     
  • Bitcoin CAD

    96,347.45
    +966.15 (+1.01%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,230.50
    +17.80 (+0.80%)
     
  • RUSSELL 2000

    2,114.35
    +44.19 (+2.13%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • NASDAQ futures

    18,497.50
    -6.25 (-0.03%)
     
  • VOLATILITY

    13.00
    +0.22 (+1.72%)
     
  • FTSE

    7,952.78
    +20.80 (+0.26%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6815
    +0.0010 (+0.15%)
     

RDInvesting Provides Investors with Free In-Depth Equity Reports on ICLR, PCYC, RNDY and RNG

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

ICON PLC (NASDAQ:ICLR - News) shares increased 3.74 percent to close at $46.85 a share Thursday. The stock traded between $45.27 and $46.98 on volume of 567,070 shares traded. Analysts at Credit Suisse have recently initiated coverage on the company with an "outperform" rating. Shares of ICON have gained approximately 13.0 percent year-to-date.

Find out more about ICON including full access to the free equity report at:
www.RDInvesting.com/ICLR

Pharmacyclics, Inc. (NASDAQ:PCYC - News) shares declined 3.46 percent to close at $105.18 a share Thursday. The stock traded between $102.60 and $108.95 on volume of 2.02 million shares traded. Analysts at Morgan Stanley have recently initiated coverage on the company with an "equal weight" rating. Shares of Pharmacyclics have fallen approximately 0.50 percent year-to-date.

ADVERTISEMENT

Find out more about Pharmacyclics including full access to the free equity report at:
www.RDInvesting.com/PCYC

Roundy's Inc. (NYSE:RNDY - News) shares spiked 7.78 percent to close at $6.65 a share Thursday. The stock traded between $6.43 and $6.95 on volume of 1.56 million shares traded. Analysts at Bank of America Merrill Lynch have recently initiated coverage on the company with a "buy" rating. Shares of Roundy's have fallen approximately 32.0 percent year-to-date.

Find out more about Roundy's including full access to the free equity report at:
www.RDInvesting.com/RNDY

RingCentral Inc. (NYSE:RNG - News) shares declined 5.89 percent to close at $17.91 a share Thursday. The stock traded between $17.88 and $19.81 on volume of 663,434 shares traded. Analysts at Macquarie have recently initiated coverage on the company with an "outperform" rating. Shares of RingCentral have fallen approximately 2.5 percent year-to-date.

Find out more about RingCentral including full access to the free equity report at:
www.RDInvesting.com/RNG

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing
info@rdinvesting.com